Under Armour, Bitcoin, AMD, Biogen, Gilead, Pfizer – Monster Commentary

This column is my opinion and expresses my views. Those views can change at a moments notice when the market changes. I am not right all the time and I do not expect to be. I disclose all my positions clearly listed on the page, and I do not trade my account on the stocks spoken of in this column unless fully disclosed. If that does not work for you stop reading and close the page. Do not bother me or harass me.

Otherwise, enjoy the column!

Subscribe to the Monster Stock Market Commentary to get the Daily Monster Market Commentary and join the 2,935 subscribers getting it for FREE!

[widget id=”wordads_sidebar_widget-41″]

Under Armour, Bitcoin, AMD, Biogen, Gilead, Pfizer – Monster Commentary

[widget id=”text-16″]

S&P 500

The S&P 500 had a relatively uneventful day, with the index finishing the day down less than 20 bps. But the thing to take note of is how the index has now failed right at 2,805 three times. Big deal? Likely not, and I would suspect we blow through that resistance tomorrow. The downside now is around 2,790, and with the start of significant earnings next week, I get the sense investor want go long into some of these upcoming results.

[vc_tweetmeme type=”follow” follow_user=”michaelmottcm” show_followers_count=”true” large_button=”true”] 

Join our 2,935 Daily Subscribers And Get This Commentary In Your E-Mail! 


The AMD seller appears to have gone up to the $12.50 level now; they must have caught word of our commentary yesterday, that is a joke. But anyway the chart continues to tell the story, and for now, AMD shares seem to want to go higher.  Maybe the seller should try the $12.75 level tomorrow. (meant to be funny, laugh!)


[widget id=”text-13″]


Biogen shares continue to trend nicely higher, with the next big test for the stock looming around $355. That is where gap from years ago is entirely closed, and a rise above $355 likely sends Biogen’s stock on to all-time highs. Also, we can see the stock has some room to rise before the relative strength index (RSI) gets to overbought levels.



Subscribe to the MCM Stock Market Commentary to get it Daily and join the 2,935 subscribers getting it for FREE!

Gilead shares have had a massive breakout and could be on their way back to $92. If Gilead and Biogen get moving, the rest of the sector follows.



Have you seen Pfizer lately? The stock looks like it ready to breakout in a big way.


[widget id=”text-17″]

Under Armour

Under Armour looks terrible here, with a clear breakdown and a stock price that appears ready to fall to $11.55.

under armour

Even fundamentally Under Armour is grossly overvalued. Shares trade at nearly 42 times 2019 earnings estimates of $0.32. Compare that to Nike’s 24 times, and Lulu’s 25 times.

UAA PE Ratio (Forward 1y) Chart

UAA PE Ratio (Forward 1y) data by YCharts

Even on an EV/EBITDA ratio, Under Armour is first now on par with Nike, and is still well north of Lulu. It comes down to simple common sense, does Under Amour deserve to trade at premium or on par with Nike? Not a chance.

UAA EV to EBITDA (Forward) Chart

UAA EV to EBITDA (Forward) data by YCharts


This chart of Bitcoin tells it all. The crypto-currency broke support around 11,800 and then it failed to rise through when it acted as resistance. See ya at 7,700.


That’s it!

[widget id=”text-14″]

Sign-up for our premium content on Seeking Alpha Market Place – “Reading The Markets”  and a get Two Week Free Trial Period

Premium Content: Benefits include the ability to reach out to Mike with questions through a chat room, direct message, or comments. 

Now JUST $25 Per Month Or $200 Per Year – Get Your Free 2-Week Trial Now!

Subscriber Mail Bag

Euro’s Big Breakout

Inflation, Tesla Plus So Much More

Predicting The Euro’s Rise


Free Articles Written By Mike:

Why Exact Sciences Will Plunge Even Further

How a Juno Takeover Could Boost Celgene

Why Facebook Stock Looks Like a Bargain

Why Ford Could Rise By Nearly 30%

Why Morgan Stanley’s Stock Is Poised to Rise by 25%

Apple Poised to Gain 14%, Defying Skeptics

Exxon Mobil May Rise 20% on the Back of Surging Oil

Qualcomm’s Stock Heads to a Crossroads

We offer daily market commentaries sent directly to your inbox or follow us on Twitter.

Join our 2,935 Daily Subscribers And Get This Commentary In Your E-Mail! Subscribe


[vc_tweetmeme type=”follow” follow_user=”michaelmottcm” show_followers_count=”true” large_button=”true”]

Photo Credit Via Flickr

Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future.

© 2017 Mott Capital Management, LLC.  Use, publication or reproduction in any media prohibited without the permission of the copyright holder.

Tags: #sp500 #bitcoin #amd #biogen #gilead #under #armour #nike #lululemon